BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 2, 2011
View Archived Issues
Heroin-like immunoconjugate protects against addiction
Read More
Privigen shows promise to treat Alzheimer's disease in preclinical test
Read More
Confirmatory phase III trial to assess Gammagard Liquid in mild to moderate Alzheimer's disease
Read More
New biomarker to differentiate benign and dangerous pancreatic cyst neoplasms
Read More
New histamine H3 receptor antagonists prepared at Takeda
Read More
Merck KGaA presents novel sphingosine kinase 1 inhibitors
Read More
Poxel discloses new AMPK activators
Read More
Novel c-Akt inhibitors synthesized at ArQule
Read More
New GLP-1 analogues and derivatives disclosed by Novo Nordisk
Read More
Bristol-Myers Squibb synthesizes novel HCV NS5A inhibitors
Read More
New therapeutic strategy identified for inflammation and autoimmune conditions
Read More
Kowa begins phase III trial of K-115 in Japan
Read More
Molecular Response and SuperGen enter translational oncology agreement
Read More
Lupin and Medicis enter agreement for formulating multiple therapeutics
Read More
Merck & Co. submits MAA for ridaforolimus in Europe
Read More
Vanda and Biotoscana Farma enter license agreement for Fanapt in Argentina
Read More
FDA places clinical hold on phase III trials of Insmed amikacin product
Read More
Teva and Active Biotech report initial results from BRAVO trial of laquinimod
Read More
Phase IIb trial of ponesimod in MS meets primary endpoint
Read More
MM-398 receives orphan drug status in pancreatic cancer
Read More
Enrollment initiated in phase II/III study of CF-101
Read More
Enrollment begins in phase III Kiobrina trial in preterm infants
Read More
Cubist Pharmaceuticals commences pivotal phase III trial of CXA-201
Read More
NYU Langone Medical Center receives grant to conduct comparative trial in coronary artery disease
Read More
NICE issues final guidance on recommendation of Ozurdex for macular edema due to RVO
Read More